Methylenedioxybenzylamphetamine

MDBZ
Clinical data
Other namesMDBZ; 3,4-Methylenedioxy-N-benzylamphetamine; N-Benzyl-MDA
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H19NO2
Molar mass269.344 g·mol−1
3D model (JSmol)
  • C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
  • InChI=1S/C17H19NO2/c1-13(18-11-14-5-3-2-4-6-14)9-15-7-8-16-17(10-15)20-12-19-16/h2-8,10,13,18H,9,11-12H2,1H3
  • Key:DWLUHTUYTBWOLO-UHFFFAOYSA-N
 NY (what is this?)  (verify)

MDBZ, also known as 3,4-methylenedioxy-N-benzylamphetamine or as N-benzyl-MDA, is a chemical compound of the phenethylamine, amphetamine, MDxx, and N-benzylphenethylamine families related to MDA.[1][2] It is the N-benzyl derivative of MDA.[1][2]

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDBZ's dose as greater than 150 mg orally and its duration as unknown.[1][2] According to Shulgin, MDBZ showed "little if any activity".[1]

Chemistry

Synthesis

The chemical synthesis of MDBZ has been described.[1]

Analogues

Analogues of MDBZ include MDA, MDMA, MDCPM, benzphetamine, benzylone (bk-MDBZ), and 2C2-NBOMe, among others.[1][2]

History

MDBZ was first described in the scientific literature by Alexander Shulgin and colleagues in 1980.[3] Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.[1]

Society and culture

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[4]

United Kingdom

MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[5]

See also

References

  1. ^ a b c d e f g h i Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://www.erowid.org/library/books_online/pihkal/pihkal103.shtml
  2. ^ a b c d Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
  3. ^ Braun U, Shulgin AT, Braun G (February 1980). "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)". J Pharm Sci. 69 (2): 192–195. Bibcode:1980JPhmS..69..192B. doi:10.1002/jps.2600690220. PMID 6102141. Archived from the original on 2025-07-12.
  4. ^ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)". Parliamentary Debates (Hansard). 23 July 1996.
  5. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.